Over the last three months, 5 analysts shared their evaluations of Puma Biotechnology PBYI, revealing numerous outlooks from bullish to bearish.
The next desk encapsulates their current scores, providing a glimpse into the evolving sentiments over the previous 30 days and evaluating them to the previous months.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Complete Scores | 5 | 0 | 0 | 0 | 0 |
| Final 30D | 1 | 0 | 0 | 0 | 0 |
| 1M In the past | 0 | 0 | 0 | 0 | 0 |
| 2M In the past | 2 | 0 | 0 | 0 | 0 |
| 3M In the past | 2 | 0 | 0 | 0 | 0 |
The 12-month value targets assessed by analysts reveal additional insights, that includes a median goal of $7.0, a excessive estimate of $7.00, and a low estimate of $7.00. The common value goal has stayed the identical, reflecting a constant view from analysts.
Understanding Analyst Scores: A Complete Breakdown
A complete examination of how monetary consultants understand Puma Biotechnology is derived from current analyst actions. The next is an in depth abstract of key analysts, their current evaluations, and changes to scores and value targets.
| Analyst | Analyst Agency | Motion Taken | Score | Present Worth Goal | Prior Worth Goal |
|---|---|---|---|---|---|
| Edward White | HC Wainwright & Co. | Maintains | Purchase | $7.00 | $7.00 |
| Edward White | HC Wainwright & Co. | Maintains | Purchase | $7.00 | $7.00 |
| Edward White | HC Wainwright & Co. | Maintains | Purchase | $7.00 | $7.00 |
| Edward White | HC Wainwright & Co. | Maintains | Purchase | $7.00 | $7.00 |
| Edward White | HC Wainwright & Co. | Maintains | Purchase | $7.00 | $7.00 |
Key Insights:
- Motion Taken: Analysts continuously replace their suggestions primarily based on evolving market situations and firm efficiency. Whether or not they ‘Keep’, ‘Elevate’ or ‘Decrease’ their stance, it displays their response to current developments associated to Puma Biotechnology. This data supplies a snapshot of how analysts understand the present state of the corporate.
- Score: Gaining insights, analysts present qualitative assessments, starting from ‘Outperform’ to ‘Underperform’. These scores mirror expectations for the relative efficiency of Puma Biotechnology in comparison with the broader market.
- Worth Targets: Gaining insights, analysts present estimates for the longer term worth of Puma Biotechnology’s inventory. This comparability reveals tendencies in analysts’ expectations over time.
Contemplating these analyst evaluations along with different monetary indicators can provide a complete understanding of Puma Biotechnology’s market place. Keep knowledgeable and make well-informed choices with our Scores Desk.
Keep updated on Puma Biotechnology analyst scores.
If you’re eager about following small-cap inventory information and efficiency you can begin by monitoring it right here.
All You Must Know About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical firm that develops and commercializes revolutionary merchandise to reinforce most cancers care and enhance remedy outcomes for sufferers. It’s at the moment commercializing NERLYNX, an oral model of neratinib, for the remedy of HER2-positive breast most cancers. Additionally it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that’s designed to disrupt mitosis resulting in apoptosis of quickly proliferating tumor cells which are depending on aurora kinase A.
A Deep Dive into Puma Biotechnology’s Financials
Market Capitalization: Surpassing business requirements, the corporate’s market capitalization asserts its dominance by way of dimension, suggesting a strong market place.
Income Challenges: Puma Biotechnology’s income development over 3 months confronted difficulties. As of 31 March, 2024, the corporate skilled a decline of roughly -17.07%. This means a lower in top-line earnings. Compared to its business friends, the corporate trails behind with a development price decrease than the common amongst friends within the Well being Care sector.
Web Margin: Puma Biotechnology’s monetary energy is mirrored in its distinctive web margin, which exceeds business averages. With a exceptional web margin of -11.0%, the corporate showcases robust profitability and efficient value administration.
Return on Fairness (ROE): Puma Biotechnology’s ROE stands out, surpassing business averages. With a formidable ROE of -9.22%, the corporate demonstrates efficient use of fairness capital and robust monetary efficiency.
Return on Belongings (ROA): Puma Biotechnology’s ROA excels past business benchmarks, reaching -2.17%. This signifies environment friendly administration of belongings and robust monetary well being.
Debt Administration: Puma Biotechnology’s debt-to-equity ratio is notably greater than the business common. With a ratio of 2.17, the corporate depends extra closely on borrowed funds, indicating a better stage of monetary threat.
Understanding the Relevance of Analyst Scores
Benzinga tracks 150 analyst corporations and experiences on their inventory expectations. Analysts sometimes arrive at their conclusions by predicting how a lot cash an organization will make sooner or later, normally the upcoming 5 years, and the way dangerous or predictable that firm’s income streams are.
Analysts attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish their scores on shares. Analysts sometimes price every inventory as soon as per quarter or at any time when the corporate has a serious replace.
Some analysts publish their predictions for metrics reminiscent of development estimates, earnings, and income to offer further steerage with their scores. When utilizing analyst scores, you will need to needless to say inventory and sector analysts are additionally human and are solely providing their opinions to buyers.
If you wish to hold monitor of which analysts are outperforming others, you’ll be able to view up to date analyst scores alongside withanalyst success scores in Benzinga Professional.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
